RxDoctor Payments Data

Heidi Joist

Nephrology · Nampa, IDNPI 1366409948

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.6% of the total across 207 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 15.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,056 and has fallen 78.2% since, to $230 in 2025.

$4,185in general payments, 2019–2025

Across 207 payments — averaging $20.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Akebia Therapeutics Inc$646
  • Otsuka America Pharmaceutical, Inc.$622
  • Vifor Pharma, Inc.$559
  • AstraZeneca$464
  • Fresenius USA Marketing, Inc.$317
  • GSK$300
  • plus $1K from 12 others

What the payments were for

  • Food & beverage$4,08398%
  • Education$1022%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,185 in reported general payments places this provider in the 85th percentile of 30 nephrology providers in Idaho.

See all nephrology providers in Idaho

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol42$39,672
AuryxiaFerric Citrate13$30,064
Sevelamer Carbonate33$3,152
Megestrol Acetate12$1,079
Calcium Acetate11$1,074
Hydralazine Hcl52$910
Carvedilol66$806
Calcitriol26$703
Amlodipine Besylate65$418
Famotidine18$315
Losartan Potassium33$313
Furosemide36$311
Atorvastatin Calcium16$310
Bumetanide15$298
Olmesartan Medoxomil15$177

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$464$39,67242 claims
Akebia Therapeutics IncAuryxia$646$30,06413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 30 nephrology providers in Idaho.

Other nephrology in Nampa

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →